Fig. 1 · Structure

Documents & Downloads

Dyphylline

Cat. No. A10339 CAS 479-18-5

Adenosine receptor antagonist

Dyphylline is a xanthine derivative with bronchodilator and vasodilator effects. It acts as an adenosine receptor antagonist and phosphodiesterase inhibitor.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In cultured neonatal mouse ovaries, dyphylline increased cAMP, Akt phosphorylation and follicle activation. LY294002 blocked the Akt-associated and follicle responses, supporting PI3K/Akt involvement in this tissue model. These experiments do not establish a PDE isoform potency or direct PI3K binding. [1]

In a purified human mPGES-1 assay, dyphylline showed competitive inhibition. The paper reports IC50 as 0.23 mM in Results and 200 μM in its Abstract. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
PDE

In Vitro Studies

At 160 μM, dyphylline increased growing follicle numbers in cultured neonatal mouse ovaries. Proliferation markers increased, whereas BAX/BCL-2 and cleaved caspase-3 readouts showed no significant change. [1]

Diprophylline had concentration- and state-dependent effects in isolated rat jejunum. It stimulated contraction at 5–40 μM and inhibited contraction at 80–160 μM. At 20 μM, it increased contraction in low-contractile-state preparations and decreased contraction in high-contractile-state preparations. [3]

Dyphylline-associated follicle activation and PI3K/Akt dependence

Cell-based study · Ovaries isolated from 3-day-postpartum female ICR mice; organ culture [1]

Dyphylline increased growing follicle numbers and Akt phosphorylation. LY294002 blocked the follicle and signaling responses. Proliferation markers increased, while measured apoptosis markers showed no significant change. This is a tissue signaling experiment, without a direct PDE isoform inhibition measurement.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Growing follicle number versus medium controldirection Increased after 4 days[1]
p-Akt and FOXO3a localization; pharmacological PI3K controldirection Increased p-Akt at 1 day and FOXO3a nuclear export at 2 days; LY294002 blocked responses and 4-day follicle activation[1]
Ovarian cAMP versus controldirection Increased[1]
BAX/BCL-2, cleaved caspase-3 and cleaved-caspase-3-positive cell countsdirection No significant effect compared with control[1]

Literature-Reported Treatment Conditions

Treatment concentration
160 μM dyphylline for Figures 3–4; 10 μM LY294002 in Figure 4 inhibitor controls. Supplement Figure S4 cAMP-panel concentration not established from readable caption.
Exposure duration
1 day for p-Akt; 2 days for FOXO3a and protein/immunofluorescence markers; 4 days for follicle counting; cAMP collection timing not established
Method
Organ culture in DMEM/F12; medium-alone control; LY294002-alone and dyphylline + LY294002 groups
Vehicle
Dyphylline stock in physiological saline; LY294002 stock in DMSO
Co-treatment
Dyphylline alone and dyphylline + LY294002; other theophylline derivatives were separate comparator groups
Reported limits
No dyphylline catalog number, purity or stereochemical composition specified. Exact vehicle matching/DMSO percentage and supplement cAMP collection timing/concentration not established; Figures 3–4 conditions are not assigned to the cAMP panel.
Methods and source locations

Compound reported in the paper: Dyphylline

Evidence applies to the named compound and stated model; stereochemical composition and Adooq lot equivalence were not established.

Figures 3A–I and 4A–I; Results: theophylline derivatives and PI3K/Akt; Supplement Figure S4E–F; Methods: ovary culture and shared analyses

Growing follicle number versus medium control: Histological follicle counting; n ≥ 3 biological replicates; mean ± SD; two-tailed unpaired t test. — Figure 3A–B and caption; Histological analysis and follicle counting

p-Akt and FOXO3a localization; pharmacological PI3K control: Western blotting, immunofluorescence and follicle counting; n ≥ 3 biological replicates; mean ± SD. — Figure 4A–I and caption

Ovarian cAMP versus control: ELISA; supplemental graphic reports mean ± SD; exact cAMP collection duration not established from readable caption. — Results paragraph beginning “Since many PDE subtypes”; Supplement Figure S4E (PDF page 5); Measurement of cAMP and cGMP levels

BAX/BCL-2, cleaved caspase-3 and cleaved-caspase-3-positive cell counts: qRT-PCR, western blotting and immunofluorescence at panel-specific 1- or 2-day time points. — Figure 3E–I and caption; Results: theophylline derivatives

Concentration- and state-dependent jejunal contractility

Cell-based study · Isolated jejunal segments from Sprague-Dawley rats; organ bath [3]

Diprophylline increased contractile amplitude at 5–40 μM and decreased it at 80–160 μM in the normal-state concentration series. At a fixed 20 μM, it increased amplitude in six low-contractile-state preparations and decreased amplitude in six high-contractile-state preparations.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Jejunal contractile amplitude versus normal baseline and equal-volume distilled-water comparatordirection Stimulation at 5–40 μM; inhibition at 80–160 μM[3]
Amplitude after 20 μM diprophylline in low and high contractile statesdirection Increased in all six low states; decreased in all six high states[3]

Literature-Reported Treatment Conditions

Treatment concentration
5, 10, 20, 40, 80 and 160 μM in normal-state series; 20 μM in state comparisons
Method
Ex vivo organ bath; concentration series and fixed-concentration state comparison
Vehicle
Stock solution pH adjusted to 7.4; Figure 1A includes equal-volume distilled-water comparator
Reported limits
No single drug-exposure duration specified in readable methods; do not infer it from representative trace spacing. Stock solvent not explicitly named in Drugs.
Methods and source locations

Compound reported in the paper: Diprophylline

Evidence applies to the named compound and stated model; stereochemical composition and Adooq lot equivalence were not established.

Figure 1A–C and caption; Results: bidirectional modulation; Methods: Drugs, tissue preparation, contractile-state definitions and statistics

Jejunal contractile amplitude versus normal baseline and equal-volume distilled-water comparator: Organ-bath recording; amplitude as % normal control; n=6 independent assays; mean ± SEM. — Figure 1A1–A2; Results first paragraph; tissue preparation

Amplitude after 20 μM diprophylline in low and high contractile states: Within-preparation pretreatment comparison; mean ± SEM (% NC), n=6; caption reports **p<0.01 versus respective pretreatment states. — Figure 1B1–C2 and caption; contractile-state definitions

Purified human mPGES-1 inhibition

Biochemical assay · Purified recombinant human mPGES-1 [2]

Dyphylline inhibited mPGES-1; kinetics were consistent with competitive inhibition. The Results report an IC50 of 0.23 mM, while the Abstract reports 200 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
mPGES-1 catalytic activityIC50 0.23 mM (Results); 200 μM (Abstract)[2]

Literature-Reported Treatment Conditions

Exposure duration
30-minute compound preincubation; 30-second enzyme reaction
Method
Purified-enzyme assay; PGH2 2.8 μM final
Vehicle
DMSO
Reported limits
Replicate count and matched-vehicle details not specified.
Methods and source locations

Compound reported in the paper: Dyphylline

Evidence applies to the named compound and stated model; stereochemical composition and Adooq lot equivalence were not established.

Page 810, Figure 4B,D and inhibitor Results; Materials p. 811; Assay pp. 811–812

mPGES-1 catalytic activity: PGE2 immunoassay after PGH2 conversion. — p. 810 Results/Figure 4B; p. 808 Abstract; Assay pp. 811–812

In Vivo Studies

In neonatal female mice, dyphylline at 40.68 mg/kg per intraperitoneal injection, twice daily for two days, increased growing follicle numbers, ovarian Akt phosphorylation and oocyte FOXO3a nuclear export relative to saline. This experiment did not test fertility improvement. [1]

Early-embryo diprophylline exposure increased heart rate in normal-appearing zebrafish embryos at several doses assessed at 48 hours post fertilization. The 5 ng/embryo group lacked a significance marker. This selected-survivor endpoint does not establish developmental safety. [4]

Neonatal mouse ovarian response to injected dyphylline

Animal study · 3-day-postpartum female ICR mice [1]

Twice-daily dyphylline injections for two days increased growing follicle numbers and ovarian Akt signaling relative to saline. The experiment evaluates early follicle activation; it does not establish fertility improvement.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Growing follicle counts and ovarian signaling relative to salinedirection Growing follicle numbers, p-Akt and FOXO3a nuclear export increased[1]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Twice daily
Treatment course
Two consecutive days
Vehicle
Physiological saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Dyphylline injection versus saline
40.68 mg/kg per injection
Physiological-saline injection groupGrowing follicle numbers, ovarian p-Akt and primordial-oocyte FOXO3a nuclear export increased.[1]
Dyphylline injection versus saline
Model: 3-day-postpartum female ICR mice
Reported limits: Caption reports collection at 12 h for signaling and 2 days for counts; exact reference to first versus last injection is not explicit. No dyphylline fertility outcome tested in this neonatal design.
Methods and source locations

Compound reported in the paper: Dyphylline

Evidence applies to the named compound and stated model; stereochemical composition and Adooq lot equivalence were not established.

Figure 5A–E and caption; Results: in vivo primordial follicle activation; Drug injection and oral administration

Growing follicle counts and ovarian signaling relative to saline: Histological counting, western blotting and immunofluorescence; n ≥ 3 biological replicates; mean ± SD; two-tailed unpaired t test. — Figure 5A–E and caption

Dyphylline injection versus saline · Figure 5A–E and caption; Methods: Drug injection and oral administration; Animals and chemicals

Heart-rate effects in zebrafish embryos

Animal study · Wild-type zebrafish embryos exposed at the 1–2-cell stage; normal-appearing survivors assessed at 48 hours post fertilization [4]

Diprophylline increased heart rate at several tested doses. Figure 5 marks significance at 1, 2.5, 10 and 20 ng/embryo, but does not mark the 5 ng/embryo comparison significant. Analysis was restricted to normal-appearing embryos, so it does not establish overall developmental safety.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Heart rate at 48 hpf relative to vehicle-injected controlsdirection Significantly increased at 1, 2.5, 10 and 20 ng/embryo; no significance marker at 5 ng/embryo[4]

Conditions shared by the study groups

Route
Yolk microinjection
Frequency
Single injection
Treatment course
Heart rate assessed at 48 hpf
Vehicle
Sterile water with 0.05% phenol red tracer
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Diprophylline dose series
1, 2.5, 5, 10 or 20 ng/embryo
Vehicle-injected negative control; metoprolol internal heart-rate control; non-injected control assessed injection effectsHeart rate increased at several doses; the 5 ng dose has no significance marker in Figure 5.[4]
Diprophylline dose series
Model: Zebrafish embryos, 1–2-cell stage
Reported limits: No exact plotted rates extracted; analysis selected normal-appearing embryos.
Methods and source locations

Compound reported in the paper: Diprophylline

Evidence applies to the named compound and stated model; stereochemical composition and Adooq lot equivalence were not established.

Table 1 dose row; Figure 5 and caption; Methods: Drugs, Microinjection, Functional cardiac effect and statistics; Results: Functional alteration

Heart rate at 48 hpf relative to vehicle-injected controls: Manual heartbeat counting for 30 s, doubled to beats/min; ten normal-appearing embryos randomly selected per drug concentration; experiments repeated at least three times. One-way ANOVA with Dunnett test. — Figure 5 diprophylline panel/caption; Functional cardiac effect; Statistical analysis

Diprophylline dose series · Table 1; Figure 5; Microinjection and Functional cardiac effect

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 479-18-5
Applications Adenosine receptor antagonist
Formula C10H14N4O4
Molecular Weight 254.24
Synonyms diprophylline
SMILES
CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CO)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 48 mg/mL (188.79 mM)
Water 48 mg/mL (188.79 mM)
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Zhang W, Gao L, Zhang X, et al. Theophylline derivatives promote primordial follicle activation via cAMP-PI3K/Akt pathway and ameliorate fertility deficits in naturally aged mice. International journal of biological sciences (2024). PMID: 39430241 DOI: 10.7150/ijbs.99936 Source material
  2. [2] Kim WI, Choi KA, Do HS, et al. Expression and purification of human mPGES-1 in E. coli and identification of inhibitory compounds from a drug-library. BMB reports (2008). PMID: 19017494 DOI: 10.5483/bmbrep.2008.41.11.808 Source material
  3. [3] Liu FF, Chen DP, Xiong YJ, et al. Characteristics of diprophylline-induced bidirectional modulation on rat jejunal contractility. The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology (2014). PMID: 24634596 DOI: 10.4196/kjpp.2014.18.1.47 Source material
  4. [4] Basnet RM, Zizioli D, Guarienti M, et al. Methylxanthines induce structural and functional alterations of the cardiac system in zebrafish embryos. BMC pharmacology & toxicology (2017). PMID: 29141695 DOI: 10.1186/s40360-017-0179-9 Source material

Added to your cart

View Cart Checkout
Loading...